AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Multiple data sets on RAD 301 will be presented at the European Molecular Imaging Meeting (EMIM).
- EMIM is scheduled to take place from 12 March to 15 March in Porto, Portugal.
- Dr Johannes Notni, a member of Radiopharm’s Scientific Advisory Board, will attend the meeting to present the data.
Clinical-stage radiotherapeutics firm Radiopharm Theranostics Limited’s (ASX: RAD) 68Ga-Trivehexin (RAD 301) technology will be on display at the European Molecular Imaging Meeting (EMIM), an international event scheduled from 12 – 15 March 2024, in Porto, Portugal.
Dr Johannes Notni, Chief Scientific Officer of TRIMT GmbH and a member of the Scientific Advisory Board of RAD, will be in attendance along with several colleagues. They will present a series of discussions on 68Ga-Trivehexin (RAD 301), which includes –
Data source: company update
About EMIM
EMIM, attracting over 1,000 international participants, serves as a platform for showcasing the latest advancements in morphological, functional, and molecular imaging, encompassing new strategies for theranostics and image-guided therapies.
Recent developments in RAD 301 trial
Data source: company update
Radiopharm recently dosed the first participant in a Phase I clinical trial for RAD 301 at the Montefiore Medical Center, Albert Einstein College of Medicine, NY, the USA. This study aims to evaluate the safety, radiation dosimetry, and imaging characteristics of RAD 301 in patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC).
RAD shares traded at AU$0.064 apiece at the time of writing on 6 March 2024.